CN113304139B - Application of Viniferifuran in preparation of xanthine oxidase inhibition drugs - Google Patents

Application of Viniferifuran in preparation of xanthine oxidase inhibition drugs Download PDF

Info

Publication number
CN113304139B
CN113304139B CN202110741146.1A CN202110741146A CN113304139B CN 113304139 B CN113304139 B CN 113304139B CN 202110741146 A CN202110741146 A CN 202110741146A CN 113304139 B CN113304139 B CN 113304139B
Authority
CN
China
Prior art keywords
xanthine oxidase
viniferifuran
application
preparation
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110741146.1A
Other languages
Chinese (zh)
Other versions
CN113304139A (en
Inventor
廖尚高
徐国波
何迅
朱勤凤
廖兴江
关焕玉
董莉
董永喜
周孟
罗喜荣
邹淑涵
张金娟
陈腾祥
王栋
杨雅欣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guizhou Medical University
Original Assignee
Guizhou Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guizhou Medical University filed Critical Guizhou Medical University
Priority to CN202110741146.1A priority Critical patent/CN113304139B/en
Publication of CN113304139A publication Critical patent/CN113304139A/en
Application granted granted Critical
Publication of CN113304139B publication Critical patent/CN113304139B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

The invention belongs to the technical field of application of effective components of traditional Chinese medicinal materials, and particularly relates to application of Viniferifuran in preparation of a xanthine oxidase inhibiting drug, wherein the Viniferifuran is a diphenyl ethylene dimer with a benzofuran structure and has a molecular formula of C28H20O6The compound has strong inhibition effect on xanthine oxidase, and can be used for preparing xanthine oxidase inhibition medicines or preventive medicines or therapeutic medicines for diseases related to xanthine oxidase.

Description

Application of Viniferifuran in preparation of xanthine oxidase inhibition drugs
Technical Field
The invention belongs to the technical field of application of effective components of traditional Chinese medicinal materials, and particularly relates to application of Viniferifuran in preparation of a xanthine oxidase inhibitor.
Background
In recent years, the incidence of gout and hyperuricemia, which is a typical purine metabolic disease, is continuously increasing, and when a large amount of uric acid is deposited in the form of sodium salt at soft tissues and joints of the body, inflammation is induced to cause gout, and thus, the important biochemical basis of gout is hyperuricemia.
Uric acid is a final product of purine metabolism, Xanthine Oxidase (XO for short) can catalyze hypoxanthine to generate Xanthine, and further metabolize the Xanthine into uric acid and free radicals, and the Xanthine Oxidase is a key enzyme for generating uric acid and an important target point for reducing the generation of uric acid. Currently, xanthine oxidase inhibitors, as a clinically common uric acid-lowering drug, can be divided into two main categories in terms of components: in clinical application, the chemically synthesized xanthine oxidase inhibitors with better effect mainly comprise benzbromarone, allopurinol, probenecid, topiroxostat, febuxostat and the like, but the drugs have large toxic and side effects, so that a human body is obviously injured.
Obtaining low-toxicity xanthine oxidase inhibitors from natural plants becomes a research hotspot, for example, in the literature, "research on xanthine oxidase inhibition activity of 9 traditional Chinese medicine extracts", 9 traditional Chinese medicine extracts (flos puerariae lobatae, herba selaginellae root, herba orthosiphoni, centipeda minima, rhizoma galangae, gynostemma pentaphylla, abrus cantoniensis hance and honeysuckle) are investigated on the xanthine oxidase inhibition activity of the extracts of the 9 traditional Chinese medicine plants. The results show that the 9 traditional Chinese medicine extracts have better inhibitory activity at 2mg/mL, and the inhibition rate is different from 33% to 79%. The semi-inhibitory concentrations of the flower of kudzuvine, the Chinese alpine rush and the honeysuckle flower are respectively 0.65, 0.96 and 0.74mg/mL, and the inhibition types of the Chinese alpine rush and the flower of kudzuvine are composite inhibition mainly including competitive inhibition.
The literature, "screening of active ingredients of uric acid-lowering traditional Chinese medicine composition and research of preparation process thereof" discloses a pharmaceutical composition consisting of a liquorice alcohol extract, a galangal alcohol extract, a dandelion alcohol extract, a chicory water extract and a plantain alcohol extract in a ratio of 10:8:7:6:10, wherein the pharmaceutical composition has the best effect.
However, most of schemes are the combination of multiple active ingredients, the inhibition effect of a single ingredient is still not ideal, and the inventor also finds that the broom extract has a certain effect of inhibiting the xanthine oxidase activity through years of research, but the main active ingredients of the broom extract are unknown, so that the research on the medication rule and the medicine preparation process is greatly influenced. Therefore, the inventor researches on the extract of the maidenhair which is safe and effective in treating the clinical gout on the basis of previous researches to discover a compound which can be used for preparing a safe and effective xanthine oxidase inhibiting medicament.
Disclosure of Invention
Aiming at the defects of the prior art, the invention provides the application of Viniferifuran in preparing xanthine oxidase inhibiting medicines.
The method is realized by the following technical scheme:
the application of the Viniferifuran in preparing a xanthine oxidase inhibition drug is characterized in that xanthine oxidase inhibition is realized by inhibiting the activity of xanthine oxidase to reduce the generation of uric acid in vivo, and diseases related to xanthine oxidase activity, such as hyperuricemia, gout, diabetic nephropathy, cardiovascular diseases and the like, are prevented and treated.
The Viniferifuran is a stilbene dimer with a benzofuran structure, and the molecular formula of the stilbene dimer is C28H20O6The chemical name is 5- {6-Hydroxy-2- (4-hydroxyphenyl) -4- [ (Z) -2- (4-hydroxyphenyl) vinyl]-1-benzofuran-3-yl}-1,3-benzenediol。
The structural formula of the Viniferifuran is as follows:
Figure BDA0003141426960000031
the Viniferifuran is extracted from natural medicines (such as sparrow roots) or is synthesized by taking stilbene as a monomer through oxidative coupling as a key reaction.
The xanthine oxidase inhibitor is prepared by taking Viniferifuran as an active ingredient and a pharmaceutically acceptable carrier or excipient.
The xanthine oxidase inhibitor is an oral preparation or an injection.
The oral preparation is one or more of granules, capsules, tablets, powder, dripping pills and sustained release preparations.
Has the advantages that:
the inventor discovers that: the stilbene dimer Viniferifuran with the benzofuran structure has a strong inhibition effect on xanthine oxidase, is an effective component of the Chinese medicinal broom root with the gout resisting effect, and can be used for preparing xanthine oxidase inhibition medicaments or medicaments for preventing or treating diseases related to the xanthine oxidase. The drug effect is verified under the condition of low concentrationIt still has significant xanthine oxidase activity inhibitory effect, IC thereof50(13.9 mu mol/L) is obviously superior to clinical allopurinol (IC)5071.7 mu mol/L) has better xanthine oxidase inhibition activity compared with clinical allopurinol.
The Viniferifuran of the invention has the antibacterial, anti-inflammatory, antiviral, antioxidant, anti-AIDS activity and liver protection effects in the history of clinical application for many years, and also has high safety performance.
The Viniferifuran provided by the invention has good adaptability, and can be prepared into various dosage forms such as injections, granules, capsules, tablets, powder, dropping pills, sustained-release agents and the like.
Drawings
FIG. 1 shows the inhibitory effect of different concentrations of Viniferuran on xanthine oxidase.
Detailed Description
The following is a detailed description of the embodiments of the present invention, but the present invention is not limited to these embodiments, and any modifications or substitutions in the basic spirit of the embodiments are included in the scope of the present invention as claimed in the claims.
Example 1
Application of Viniferiferan in preparation of xanthine oxidase inhibition drugs, wherein Viniferan is diphenyl ethylene dimer with benzofuran structure, and molecular formula of Viniferan is C28H20O6The chemical name is 5- {6-Hydroxy-2- (4-hydroxyphenyl) -4- [ (Z) -2- (4-hydroxyphenyl) vinyl]-1-benzofuran-3-yl}-1,3-benzenediol；
The structural formula of the Viniferifuran is as follows:
Figure BDA0003141426960000041
the Viniferifuran is extracted from natural medicines (such as sparrow roots) or is synthesized by taking stilbene as a monomer through oxidative coupling as a key reaction.
The xanthine oxidase inhibition is characterized in that the xanthine oxidase inhibition is used for inhibiting the activity of the xanthine oxidase, reducing the generation of uric acid in vivo and preventing and treating diseases related to the xanthine oxidase activity, such as hyperuricemia, gout, diabetic nephropathy, cardiovascular diseases and the like.
The xanthine oxidase inhibitor is prepared by taking Viniferifuran as an active ingredient and a pharmaceutically acceptable carrier or excipient.
The xanthine oxidase inhibitor is an oral preparation or an injection;
the oral preparation is one or more of granules, capsules, tablets, powder, dripping pills and sustained release preparations;
experimental example 1
XO inhibitory activity test: using a 96-well plate at 25 ℃ in a total reaction volume of 200. mu.L, 50. mu.L of the enzyme solution (final reaction concentration: 0.05U/mL) and 50. mu.L of the sample solution were added first, and after incubation at 25 ℃ for 15min, 50. mu.L of the xanthine substrate (final concentration: 150. mu. mol/L) was added to initiate the reaction. After incubation at 25 ℃ for 20min, the reaction was stopped by adding 50. mu.L of 1mol/L hydrochloric acid solution. The absorbance values were measured at 290 nm. Taking the difference value of the value and the OD value at the time of incubation for 0min as a final detection result; the OD value of the blank sample (i.e., the sample solution was replaced with PBS containing 5% DMSO to determine the maximum reactivity of the enzyme without the test drug) was measured in the same manner, and the inhibition rate of each extract was calculated according to the following formula: inhibition (%) × (1 — average OD value of test sample/average OD value of blank sample) × 100%. Data analysis was performed using Graphpadprism 6.0 software. Calculating the drug concentration at which half of the xanthine oxidase is inhibited, i.e. IC50. Allopurinol is used as a positive drug; the activity results are shown in table 1;
wherein, the preparation of the enzyme solution: weighing a proper amount of XO, and dissolving with 1mL of water to obtain XO stock solution with the concentration of 100U/mL; the stock solution was dispensed into 10mL EPP tubes at 50. mu.L per tube, and stored in a refrigerator at-80 ℃. Taking a proper amount of the stock solution, and diluting with PBS to obtain XO solution with the concentration of 0.2U/mL. After the solution is prepared, the solution is immediately stored in a refrigerator at 0 ℃.
Preparation of sample solution: an appropriate amount of Viniferifuran is precisely weighed, dissolved in DMSO and diluted with PBS to prepare a sample mother solution with the mass concentration of 1000 mug/mL. And diluting the mother liquor step by using PBS containing DMSO as a solvent by a double dilution method to prepare sample solutions with the mass concentrations of 1000, 500, 250, 125, 62.5, 31.3 and 15.6 mu g/mL respectively, wherein the DMSO content is 1%.
Preparation of allopurinol control solution: accurately weighing a proper amount of allopurinol, dissolving the allopurinol in DMSO, and adding a proper amount of PBS for dilution to prepare allopurinol mother liquor with the mass concentration of 500 mug/mL for later use. The mother liquor is diluted step by using PBS containing DMSO as a solvent by a double dilution method to prepare control solutions with the mass concentrations of 500, 250, 125, 62.5, 31.3, 15.63, 7.82 and 3.91 mu g/mL respectively, wherein the DMSO content is 1%.
Preparation of xanthine substrate solution: weighing a proper amount of xanthine, adding PBS, adjusting the pH to 7.5 by NaOH and HCl solutions at room temperature, and performing ultrasonic dissolution to prepare xanthine substrate solutions with the concentrations of 1200, 1000, 800, 600 and 400 mu mol/L respectively.
TABLE 1 inhibition and median Inhibition (IC) of XO by Viniferifuran at different concentrations50)
Figure BDA0003141426960000061
As can be seen from Table 1: IC compared with positive allopurinol50(71.7. mu. mol/L) and a lower inhibition at low concentrations (8.3% and 4.2% at 12.5 and 6.25. mu. mol/L, respectively), the IC of Viniferifuran claimed in the present application50Is 13.9 mu mol/L, still has higher inhibition rate under low concentration (59.1 percent and 32.1 percent respectively at 12.5 and 6.25 mu mol/L), has outstanding inhibition effect on xanthine oxidase and is obviously better than allopurinol.

Claims (1)

  1. The application of Viniferifuran in preparing the medicine for preventing and treating hyperuricemia and gout by inhibiting xanthine oxidase activity is characterized in that the Viniferifuran is a diphenyl ethylene dimer with a benzofuran structure, and the molecular formula of the diphenyl ethylene dimer is C28H20O6The chemical name is 5- {6-Hydroxy-2- (4-hydroxyphenyl) -4- [ (Z) -2- (4)-hydroxyphenyl)vinyl]-1-benzofuran-3-yl}-1,3-benzenediol；
    The structural formula of the Viniferifuran is as follows:
    Figure DEST_PATH_IMAGE002
    。
CN202110741146.1A 2021-06-30 2021-06-30 Application of Viniferifuran in preparation of xanthine oxidase inhibition drugs Active CN113304139B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110741146.1A CN113304139B (en) 2021-06-30 2021-06-30 Application of Viniferifuran in preparation of xanthine oxidase inhibition drugs

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110741146.1A CN113304139B (en) 2021-06-30 2021-06-30 Application of Viniferifuran in preparation of xanthine oxidase inhibition drugs

Publications (2)

Publication Number Publication Date
CN113304139A CN113304139A (en) 2021-08-27
CN113304139B true CN113304139B (en) 2022-04-29

Family

ID=77381332

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110741146.1A Active CN113304139B (en) 2021-06-30 2021-06-30 Application of Viniferifuran in preparation of xanthine oxidase inhibition drugs

Country Status (1)

Country Link
CN (1) CN113304139B (en)

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1600304A (en) * 2003-09-23 2005-03-30 中国医学科学院药物研究所 Application of extractive of ussurian grape on curing inflammatory disease
CN101057840A (en) * 2006-04-21 2007-10-24 中国医学科学院药物研究所 Application of Vam3 in preparing medicine for treating chronic obstructive disease of lung
WO2011012715A1 (en) * 2009-07-31 2011-02-03 Ascendis Pharma As Biodegradable polyethylene glycol based water-insoluble hydrogels
CN102095825A (en) * 2010-12-08 2011-06-15 中国科学院长春应用化学研究所 Method for screening xanthine oxidase inhibitor by ultra performance liquid chromatography and mass spectrometry
WO2013160340A1 (en) * 2012-04-25 2013-10-31 Ascendis Pharma A/S Prodrugs of hydroxyl-comprising drugs
CN104546820A (en) * 2013-10-09 2015-04-29 中国医学科学院药物研究所 Application of stilbene dimer in preventing and curing hematopoietic stem cell radioactive damage
CN109721580A (en) * 2017-10-27 2019-05-07 中国医学科学院药物研究所 The plain derivative of 3- phenyl -7,8- dehydrogenation grapevine penta, its preparation method and pharmaceutical composition and purposes
CN109721579A (en) * 2017-10-27 2019-05-07 中国医学科学院药物研究所 The plain derivative of 7,8- dehydrogenation grapevine penta, its preparation method and pharmaceutical composition and purposes
CN109893522A (en) * 2017-12-08 2019-06-18 中国医学科学院药物研究所 Amurensin H derivative is treating and preventing the application in Chronic Obstructive Pulmonary Disease
CN109897021A (en) * 2017-12-07 2019-06-18 中国医学科学院药物研究所 The plain derivative of grapevine penta, its preparation method and pharmaceutical composition and purposes
CN110368419A (en) * 2019-07-02 2019-10-25 贵州医科大学 Application of the polygonum capitatum in terms of adjusting uric acid
CN110433153A (en) * 2018-05-03 2019-11-12 中国医学科学院药物研究所 A kind of Amurensin H derivative is treating and preventing the application in liver related disease
CN111096963A (en) * 2018-10-25 2020-05-05 中国医学科学院药物研究所 Application of Amurensin H derivative EAPP in treatment and prevention of aplastic anemia
CN113754619A (en) * 2021-10-09 2021-12-07 广州大学 Method for preparing polysubstituted benzofuran-4-formic acid compound under catalysis of ruthenium

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1600304A (en) * 2003-09-23 2005-03-30 中国医学科学院药物研究所 Application of extractive of ussurian grape on curing inflammatory disease
CN101057840A (en) * 2006-04-21 2007-10-24 中国医学科学院药物研究所 Application of Vam3 in preparing medicine for treating chronic obstructive disease of lung
WO2011012715A1 (en) * 2009-07-31 2011-02-03 Ascendis Pharma As Biodegradable polyethylene glycol based water-insoluble hydrogels
CN102095825A (en) * 2010-12-08 2011-06-15 中国科学院长春应用化学研究所 Method for screening xanthine oxidase inhibitor by ultra performance liquid chromatography and mass spectrometry
WO2013160340A1 (en) * 2012-04-25 2013-10-31 Ascendis Pharma A/S Prodrugs of hydroxyl-comprising drugs
CN104546820A (en) * 2013-10-09 2015-04-29 中国医学科学院药物研究所 Application of stilbene dimer in preventing and curing hematopoietic stem cell radioactive damage
CN109721580A (en) * 2017-10-27 2019-05-07 中国医学科学院药物研究所 The plain derivative of 3- phenyl -7,8- dehydrogenation grapevine penta, its preparation method and pharmaceutical composition and purposes
CN109721579A (en) * 2017-10-27 2019-05-07 中国医学科学院药物研究所 The plain derivative of 7,8- dehydrogenation grapevine penta, its preparation method and pharmaceutical composition and purposes
CN109897021A (en) * 2017-12-07 2019-06-18 中国医学科学院药物研究所 The plain derivative of grapevine penta, its preparation method and pharmaceutical composition and purposes
CN109893522A (en) * 2017-12-08 2019-06-18 中国医学科学院药物研究所 Amurensin H derivative is treating and preventing the application in Chronic Obstructive Pulmonary Disease
CN110433153A (en) * 2018-05-03 2019-11-12 中国医学科学院药物研究所 A kind of Amurensin H derivative is treating and preventing the application in liver related disease
CN111096963A (en) * 2018-10-25 2020-05-05 中国医学科学院药物研究所 Application of Amurensin H derivative EAPP in treatment and prevention of aplastic anemia
CN110368419A (en) * 2019-07-02 2019-10-25 贵州医科大学 Application of the polygonum capitatum in terms of adjusting uric acid
CN113754619A (en) * 2021-10-09 2021-12-07 广州大学 Method for preparing polysubstituted benzofuran-4-formic acid compound under catalysis of ruthenium

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
9种通络祛风中药提取物对黄嘌呤氧化酶的体外抑制活性研究;李芮，等;《中国药房》;20200327(第06期);第42-47页 *
Anti-inflammatory effect of amurensin H on asthma-like reaction induced by allergen in sensitized mice;Yi-tang LI，等;《Acta Pharmacologica Sinica》;20060615(第06期);第101-106页 *
Pharmacokinetic analysis and tissue distribution of Vam3 in the rat by a validated LC-MS/MS method;Ruixia Zhang，等;《Acta Pharmaceutica Sinica B》;20150515(第03期);第94-103页 *
Synthesis of Amurensin H, a New Resveratrol Dimer from the Roots of Vitis Amurensis;K.S. Huang，等;《Chinese Chemical Letters》;19991030(第10期);第817-820页 *
Theoretical studies on the antioxidant activity of viniferifuran;Yaxuan Shang，等;《New Journal of Chemistry》;20190902;第43卷(第39期);第15736-15742页 *
Vam3对小鼠体外胸腺细胞的辐射防护效应;刘冰，等;《辐射研究与辐射工艺学报》;20160420(第02期);第38-43页 *
Vam3对硝普钠诱导的大鼠关节软骨细胞凋亡及SIRT1与p53表达的影响;姜仁涛，等;《药学学报》;20140531;第49卷(第5期);第608-614页 *
Vams及其主要成分Vam3抗慢性气道炎症作用及机制研究;李怡棠;《中国博士学位论文全文数据库电子期刊 医药卫生科技辑》;20061115(第11期);第E057-145页 *
二苯乙烯化合物Vam3对哮喘小鼠气道炎症以及ICAM-1、NF-κB和MMP-9活性的影响;杨莉，等;《药学学报》;20101212(第12期);第41-46页 *
二苯乙烯苷通过MAPK、HIF-1α和p53通路减轻缺氧/复氧损伤诱导的支气管上皮细胞凋亡;连浦峤，等;《药学学报》;20170712(第07期);第110-120页 *
染料木素、芹菜素、槲皮素、芦丁和落新妇苷对高尿酸血症小鼠黄嘌呤氧化酶活性及血清尿酸水平的影响;黄敬群，等;《中国药理学通报》;20110420(第04期);第123-127页 *
药用植物中黄嘌呤氧化酶抑制剂的研究进展;张晨辉，等;《中成药》;20181020(第10期);第145-150页 *
金雀花根中黄嘌呤氧化酶抑制活性成分研究;王栋，等;《中药材》;20211031;第44卷(第10期);第608-614页 *

Also Published As

Publication number Publication date
CN113304139A (en) 2021-08-27

Similar Documents

Publication Publication Date Title
CN109674958B (en) Traditional Chinese medicine composition with effect of reducing uric acid and preparation method and application thereof
CN113368248B (en) Composition for protecting cells comprising cyclamic acid-proline as active ingredient
CN111110824B (en) Medicinal composition for strengthening body resistance and rescuing lung and application thereof
CA3166282A1 (en) Use of pharmaceutical composition for preventing and treating novel coronavirus pneumonia
CN102086172A (en) Medicinal salts of saxagliptin and preparation methods of medicinal salts
JP5524196B2 (en) Pharmaceutical composition for the treatment of diabetes
CN113304139B (en) Application of Viniferifuran in preparation of xanthine oxidase inhibition drugs
CN104983729B (en) Catechin compounds and gallic acid combination are preparing the new application in treating antihyperuricemic disease drug
CN113304140A (en) Application of Caraphenol A in preparation of xanthine oxidase inhibition drugs
US9943560B2 (en) Medical compositions containing liquorice extracts with synergistic effect
CN109350632A (en) A kind of Chinese medicine composition for antipyretic-antalgic
CN113304138B (en) Application of Vitisinol D in preparation of xanthine oxidase inhibition drugs
CN108403980B (en) Hypoglycemic plant extract effective part and preparation method and application thereof
AU2018101586A4 (en) Uses of polydatin
CN106943408B (en) Application of tetramethyluric acid in preventing and treating diabetes
CN106822152B (en) Pharmaceutical composition and application thereof
CN111116395B (en) Multi-iodo aromatic acid compound and application thereof in resisting adenovirus 7
CN111195247B (en) Alpha-glucosidase inhibitor and application thereof in hypoglycemic drugs
CN113143925B (en) Application of metformin hydrochloride in preparation of preparation for treating crizotinib cardiotoxicity
CN114272254B (en) Application of combination of glycyrrhetinic acid and paeoniflorin in treating liver injury and liver fibrosis
CN111704622B (en) Flavanol-menthane heterozygote, pharmaceutical composition thereof, preparation method and application thereof
CN113398114B (en) Application of 3,7,8,4' -tetrahydroxyflavone in preparing anti-cardiovascular disease medicine
CN103893512B (en) A kind of Chinese medicine composition for treating urarthritis
JP6563375B2 (en) Nephropathy treatment
CN111643490A (en) Pharmaceutical composition with maltose hydrolase inhibition activity and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant